Who is the manufacturer of Sorrento Bioglass Bone Graft Substitute?

Xenco Medical, LLC filed the 510(k) submission for Sorrento Bioglass Bone Graft Substitute (K173933).

What is the FDA product code for Sorrento Bioglass Bone Graft Substitute?

MQV. It is classified under 21 CFR 888.3045 as a Class 2 device in the Orthopedic panel.

What is the regulatory pathway for Sorrento Bioglass Bone Graft Substitute?

510(k) clearance (submission type: Traditional).

Who can help prepare an FDA 510(k) submission like Sorrento Bioglass Bone Graft Substitute?

Innolitics — a medical-device software consultancy — provides regulatory and engineering support for FDA 510(k) submissions. See https://innolitics.com/services/510ks/ or contact https://innolitics.com/contact.

Sorrento Bioglass Bone Graft Substitute

Q: What are the predicate devices for Sorrento Bioglass Bone Graft Substitute?

Sorrento™ Bone Graft Substitute (K141429).

K173933 · Xenco Medical, LLC · MQV · Sep 13, 2018 · Orthopedic

Device Facts

Record ID	K173933
Device Name	Sorrento Bioglass Bone Graft Substitute
Applicant	Xenco Medical, LLC
Product Code	MQV · Orthopedic
Decision Date	Sep 13, 2018
Decision	SESE
Submission Type	Traditional
Regulation	21 CFR 888.3045
Device Class	Class 2
Attributes	Therapeutic

Intended Use

Sorrento Bone Graft Substitutes are intended for use as a bone void filler to fill voids or gaps of the skeletal system in the extremities and pelvis not intrinsic to the bony structure. Sorrento Bone Graft Substitutes are also indicated for use in the treatment of surgically created osseous defects created from traumatic injury to the bone. Sorrento Bone Graft Substitutes must be wetted with bone marrow aspirate. Following placement in the bony void or gap (defect), Sorrento Bone Graft Substitutes are resorbed and replaced with bone during the healing process

Device Story

Sorrento Bioglass Bone Graft Substitute is a resorbable bone void filler; matrix of highly purified collagen, beta-tricalcium phosphate (TCP) granules, and Bioglass 45S5. Provided sterile for single-use. Clinician wets device with patient's bone marrow aspirate before placement into skeletal voids or osseous defects in extremities/pelvis. Device acts as scaffold; resorbed and replaced by host bone during healing. Used by surgeons in clinical settings to treat traumatic bone defects. Benefits patient by providing osteoconductive matrix to facilitate bone regeneration.

Clinical Evidence

No clinical data. Evidence consists of biocompatibility testing (ISO 10993-1), bench testing (ASTM F1088, F2212, F1538), and an animal study. Animal study used a rabbit distal femoral defect model to compare subject device, predicate (K141429), and reference (K083033) at 3, 6, and 12 weeks. Performance evaluated via radiography and histomorphometry; results demonstrated substantial equivalence.

Technological Characteristics

Resorbable bone void filler. Materials: Type I bovine collagen (ASTM F2212), beta-tricalcium phosphate (ASTM F1088), and Bioglass 45S5 (ASTM F1538). Form: Porous collagen sponge strip with trabecular structure. Porosity >80% (beta-TCP) and 64-78% (Bioglass). Sterilization: Sterile, single-use. No software or electronic components.

Indications for Use

Indicated for use as a bone void filler in the extremities and pelvis for voids, gaps, or surgically created osseous defects resulting from traumatic injury. Not for use in areas intrinsic to bony structure stability. Requires wetting with bone marrow aspirate.

Regulatory Classification

Identification

A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.

Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.

Predicate Devices

Sorrento™ Bone Graft Substitute (K141429)

Reference Devices

Vitoss® Foam Bone Graft Material, Vitoss® Bioactive Foam Bone Graft Substitute (K083033)

Related Devices

K141429 — SORRENTO BONE GRAFT SUBSTITUTE · Haider Biologics, LLC · Feb 23, 2015
K091302 — INTEGRA MOZAIK AND OS MOLDABLE MORSELS · Integra LifeSciences Corporation · Dec 4, 2009
K191074 — Sorrento Bone Graft Substitute · Xenco Medical, LLC · Sep 27, 2019
K170917 — Bi-Ostetic Bioactive Glass Foam · Berkeley Advanced Biomaterials · Oct 30, 2017
K120354 — BETA-TCP GRANULES · Skeletal Kinetics, LLC · Mar 21, 2013

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health and Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. September 13, 2018 Xenco Medical, LLC Gustavo R. Prado, Ph.D. Vice President, R&D 9930 Mesa Rim Road San Diego, California 92121 Re: K173933 Trade/Device Name: Sorrento™ Bioglass Bone Graft Substitute Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone void filler device Regulatory Class: Class II Product Code: MQV Dated: August 14, 2018 Received: August 15, 2018 Dear Dr. Prado: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's {1}------------------------------------------------ requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm. For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Laurence D. Coyne -S For Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ ## Indications for Use Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below. 510(k) Number (if known) K173933 Device Name Sorrento™ Bioglass Bone Graft Substitute ### Indications for Use (Describe) Sorrento Bone Graft Substitutes are intended for use as a bone void filler to fill voids or gaps of the skeletal system in the extremities and pelvis not intrinsic to the bony structure. Sorrento Bone Graft Substitutes are also indicated for use in the treatment of surgically created osseous defects created from traumatic injury to the bone. Sorrento Bone Graft Substitutes must be wetted with bone marrow aspirate. Following placement in the bony void or gap (defect), Sorrento Bone Graft Substitutes are resorbed and replaced with bone during the healing process Type of Use (Select one or both, as applicable) | ☒ Prescription Use (Part 21 CFR 801 Subpart D) | |------------------------------------------------------------------------------------| | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | scription Use (Part 21 CFR 601 Subpart D) | | Over-The-Counter Use (21 CFR 801 Subpart C) ### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. ### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ Image /page/3/Picture/0 description: The image is a logo for Xiron Medical. The logo is a green hexagon with the text "Xiron Medical" in white letters. The "X" is larger than the other letters and is located in the upper left corner of the hexagon. The word "iron" is smaller and is located to the right of the "X". The word "Medical" is even smaller and is located below the word "iron". The hexagon is made up of several smaller triangles of different shades of green. # 510(k) SUMMARY #### l. SUBMITTER Xenco Medical, LLC. Contact Person: Gustavo Prado PhD Email: gprado@xencomedical.com 9930 Mesa Rim Road San Diego, CA 92121 USA Phone: 858-202-1505 ext 202 Fax: 858-202-1549 Date Prepared: 08/14/2018 Establishment Registration: 3011181154 #### II. DEVICE ### SUBJECT DEVICE Trade Name: Sorrento™ Bioglass Bone Graft Substitute Common Name: bone void filler Classification Name: Resorbable Calcium Salt Bone Void Filler Device Regulation: 21 CFR 888.3045 Device Class: Class II Product Code: MQV Review Panel: Orthopedic ### PREDICATE DEVICE | 510(k) Number | Product Code | Trade Name | Manufacturer | |----------------------|-----------------|-----------------------------------------------------------------------------------------------|---------------------| | K141429 Primary | MQV | Sorrento™ Bone Graft Substitute | Xenco Medical, LLC. | | K083033 Reference | MQV | Vitoss® Foam Bone Graft Material, Vitoss® Bioactive Foam Bone Graft Substitute | Orthovita, Inc. | {4}------------------------------------------------ Image /page/4/Picture/0 description: The image is a logo for Xpert Medical. The logo is a green hexagon with a white outline. Inside the hexagon, the text "Xpert Medical" is written in white. The "X" is larger than the rest of the text. The hexagon is made up of smaller triangles of different shades of green. #### lll. DEVICE DESCRIPTION Sorrento BioGlass Bone Graft Substitute is a resorbable bone void filler made from a matrix of highly purified collagen (ASTM F2212) that has high porosity beta tricalcium phosphate (TCP) granules (ASTM F1088) and Bioglass 45S5 (ASTM F1538) dispersed throughout. The implant is provided as sterile, for single-use in double peel packages. #### IV. INDICATIONS FOR USE Sorrento Bone Graft Substitutes are intended for use as a bone void filler to fill voids or gaps of the skeletal system in the extremities and pelvis not intrinsic to the stability of the bony structure. Sorrento Bone Graft Substitutes are also indicated for use in the treatment of surgically created osseous defects or osseous defects created from traumatic injury to the bone. Sorrento Bone Graft Substitutes must be wetted with bone marrow aspirate. Following placement in the bony void or gap (defect), Sorrento Bone Graft Substitutes are resorbed and replaced with bone during the healing process #### V. TECHNOLOGICAL CHARACTERISTICS The subject device is substantially equivalent to the cited legally marketed predicate Sorrento (K141429) device. The subject device has equivalent technological characteristics including design, materials, operating principle and indications for use, physical structure, product sizing, chemical composition, mineral phase, porosity, and resorption. | Characteristic | Sorrento BioGlass (Subject Device) | Sorrento (Predicate, K141429) | Vitoss Foam Bone Graft Substitute and Vitoss Bioactive Foam Bone Graft Substitute (Reference, K083033) | |------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------| | Materials | • Beta Tricalcium Phosphate per ASTM F1088 • Type I bovine collagen per ASTM F2212 • Bioglass 45S5 per ASTM F1538 | • Beta Tricalcium Phosphate per ASTM F1088 • Type I bovine collagen per ASTM F2212 | • Beta Tricalcium Phosphate per ASTM F1088 • Type I bovine collagen per ASTM F2212 • Bioglass (Bioactive version only) | | Physical Structure (Form) | • Porous collagen sponge (strip) with beta- TCP/Bioglass granules • Trabecular structure similar to cancellous bone | • Porous collagen sponge (strip) with beta-TCP granules • Trabecular structure similar to cancellous | • Porous collagen sponge (strip) with beta-TCP granules • Trabecular structure similar to cancellous bone | ## Chart comparing subject device to the predicate devices: {5}------------------------------------------------ Image /page/5/Picture/0 description: The image is a logo for Excel Workbook. The logo is a green hexagon with the words "Excel Workbook" written in white text. The "X" is larger than the other letters. The background of the hexagon is a mosaic of different shades of green. | | | bone | | |--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Dosage Forms (Sizing) | • 2cc (25 x 20 x 4 mm) • 5 cc (25 x 50 x 4 mm) • 10 cc (100 x 20 x 5 mm) • 12 cc (100 x 20 x 6 mm) • 20 cc (100 x 25 x 8 mm) • 24 cc (25 x 240 x 4 mm) | • 5 cc (25 x 50 x 4 mm) • 10 cc (100 x 20 x 5 mm) • 12 cc (100 x 20 x 6 mm) • 20 cc (100 x 25 x 8 mm) • 24 cc (25 x 240 x 4 mm) | • 2 cc (25 x 20 x 4mm) • 5 cc (25 x 50 x 4mm) (Bioactive) • 10 cc (100 x 25 x 4 mm) (Bioactive) • 10 cc (25 x 50 x 8) • 20 cc (100 x 25 x 8 mm) (Bioactive) • 24 cc (25 x 240 x 4 mm) • 30 cc (75 x 100 x 4 mm) | | Chemical Composition (Chemistry) | • Calcium salt with Type I bovine collagen and Bioglass (~90:5:5 w/w) | • Calcium salt with Type I bovine collagen (~95:5 w/w) | • Calcium salt with Type I bovine collagen (~80:20 w/w) • Calcium salt with Type I bovine collagen and Bioglass | | Mineral Phase | • Beta-Tricalcium Phosphate Ca3(PO4)2 | • Beta-Tricalcium Phosphate Ca3(PO4)2 | • Beta-Tricalcium Phosphate Ca3(PO4)2 | | Porosity (beta-TCP) | • Highly porous, >80% • Bioglass 64-78% | • Highly porous, >80% | • Approximately 90% (non- Bioactive) | | Pore Size (range) (Beta-TCP) | • ~1-732 μm (312 ± 140 μm) bioglass | • ~1-732 μm (312 ± 140 μm) | • ~12-700 μm (non- Bioactive) | | Resorption (Dissolution/ Solubility) | • Resorbable | • Resorbable | • Demonstrated 80% resorbed at 12 weeks | Xenco Medical, LLC. - Sorrento™ Bioglass Bone Graft Substitute September 11th, 2018 #### VI. PERFORMANCE DATA The following performance data were provided in support of the substantial equivalence determination. ### Biocompatibility Testing Analysis was performed according to ISO 10993-1:2009 and biological effects were considered based on FDA Guidance. "Use of International Standard ISO 10993-1, Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process." Material-Mediated Pyrogenicity, Cytotoxicity, Irritation, Sensitization, and Implantation testing was performed and showed acceptable biological safety profiles. Bacterial endotoxin testing was performed and confirmed an endotoxin level within the established acceptance criteria. ### Bench Testing Substantial equivalence of the Sorrento BioGlass Bone Graft Substitute was supported by evaluation per ASTM F1088 (for beta tricalcium phosphate), ASTM F2212 (for collagen) and ASTM F1538 (Bioglass). {6}------------------------------------------------ Image /page/6/Picture/0 description: The image is a logo for a company or product called "XM". The logo is a green hexagon with the letters "X" and "M" in white. The "X" is larger than the "M", and the "M" is slightly offset to the right. The hexagon is made up of several smaller triangles, which gives it a faceted appearance. The logo is simple and modern, and the green color suggests that the company or product is related to nature or the environment. Xenco Medical, LLC. - Sorrento™ Bioglass Bone Graft Substitute September 11th, 2018 > Bioactivity was also evaluated through analysis by SEM and FTIR to confirm the ability of the subject device to form an in vitro layer of apatite. ## Animal Study A distal femoral defect model in rabbits was used to compare the subject device to the predicate device Sorrento Bone Graft Substitute (K141429) and the reference device Vitoss Foam Bone Graft Substitute (K083033) at 3, 6 and 12 weeks following implantation. Performance was evaluated radiographically and histomorphometrically. Study data demonstrated that the subject device is substantially equivalent with the predicate and reference devices. In addition, substantial equivalence of the Sorrento BioGlass Bone Graft Substitute was supported by evaluation per ASTM F1088 (for beta tricalcium phosphate) and ASTM F2212 (for collagen) and ASTM F1538 (Bioglass). ### Clinical Studies Clinical performance data was not required to determine substantial equivalence #### VII. CONCLUSIONS Conclusions drawn from the non-clinical tests demonstrated that the subject device possessed at least equivalent performance characteristics as the predicate device, and that overall the subject device is substantially equivalent.